Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesoPher maintenance therapy after chemotherapy for pleural mesothelioma
NL-OMON55474Phase 2Active, not recruiting
- Sponsor
- Amphera B.V.
- Start
- Jun 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pleural mesothelioma comparing MesoPher plus best supportive care with Best supportive care alone (2 arms). Primary endpoint: Overall survival. Started Jun 2018; status: active, not recruiting.
02
Drugs
MesoPher
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON55474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55474.